Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
E Sbidian, A Chaimani, R Guelimi… - Cochrane Database …, 2023 - cochranelibrary.com
Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …
manifestations, or both, and it has a major impact on quality of life. Although there is …
[HTML][HTML] Targeted immunotherapy for autoimmune disease
SM Jung, WU Kim - Immune network, 2022 - ncbi.nlm.nih.gov
In the past few decades, biological drugs and small molecule inhibitors targeting
inflammatory cytokines, immune cells, and intracellular kinases have become the standard …
inflammatory cytokines, immune cells, and intracellular kinases have become the standard …
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind …
K Reich, KA Papp, A Blauvelt, RG Langley… - The Lancet, 2021 - thelancet.com
Background There is an unmet need for a treatment for psoriasis that results in complete
skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody …
skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody …
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double …
JF Merola, R Landewé, IB McInnes, PJ Mease… - The Lancet, 2023 - thelancet.com
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
Bimekizumab versus secukinumab in plaque psoriasis
K Reich, RB Warren, M Lebwohl… - … England Journal of …, 2021 - Mass Medical Soc
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both
interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared …
interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared …
Inflammatory bowel disease: a review of pre-clinical murine models of human disease
B Katsandegwaza, W Horsnell, K Smith - International Journal of …, 2022 - mdpi.com
Crohn's disease (CD) and ulcerative colitis (UC) are both highly inflammatory diseases of
the gastrointestinal tract, collectively known as inflammatory bowel disease (IBD). Although …
the gastrointestinal tract, collectively known as inflammatory bowel disease (IBD). Although …
Antibodies to watch in 2022
H Kaplon, A Chenoweth, S Crescioli, JM Reichert - MAbs, 2022 - Taylor & Francis
In this 13th annual installment of the annual 'Antibodies to Watch'article series, we discuss
key events in commercial antibody therapeutics development that occurred in 2021 and …
key events in commercial antibody therapeutics development that occurred in 2021 and …
The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications
R Singh, S Koppu, PO Perche, SR Feldman - International journal of …, 2021 - mdpi.com
Psoriasis is the result of uncontrolled keratinocyte proliferation, and its pathogenesis
involves the dysregulation of the immune system. The interplay among cytokines released …
involves the dysregulation of the immune system. The interplay among cytokines released …
Bimekizumab versus adalimumab in plaque psoriasis
RB Warren, A Blauvelt, J Bagel, KA Papp… - … England Journal of …, 2021 - Mass Medical Soc
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-
17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the …
17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the …
Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial
Importance Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high
burden for patients and limited existing therapeutic options. Objective To evaluate the …
burden for patients and limited existing therapeutic options. Objective To evaluate the …